[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1988009164A1 - Preparation pharmaceutique a action oestrogenique - Google Patents

Preparation pharmaceutique a action oestrogenique Download PDF

Info

Publication number
WO1988009164A1
WO1988009164A1 PCT/SU1987/000065 SU8700065W WO8809164A1 WO 1988009164 A1 WO1988009164 A1 WO 1988009164A1 SU 8700065 W SU8700065 W SU 8700065W WO 8809164 A1 WO8809164 A1 WO 8809164A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
dose
preparation
hours
product
Prior art date
Application number
PCT/SU1987/000065
Other languages
English (en)
Russian (ru)
Inventor
Anvar Gafurovich Kurmukov
Khafiza Saidganievna Akhmedkhodzhaeva
Makhamat Babadzhanovich Sultanov
Ashraf Ismailovich Saidkhodzhaev
Georgy Konstantinovich Nikonov
Akhmed Umarovich Mamatkhanov
Mukhamed-Rishad Iskanderovich Shamsutdinov
Talat Taibbekovich Shakirov
Original Assignee
Institut Khimii Rastitelnykh Veschestv Akademii Na
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Khimii Rastitelnykh Veschestv Akademii Na filed Critical Institut Khimii Rastitelnykh Veschestv Akademii Na
Priority to DE19873790958 priority Critical patent/DE3790958T1/de
Priority to CH3458987A priority patent/CH672251A5/de
Priority to JP87505402A priority patent/JPH02500362A/ja
Priority to PCT/SU1987/000065 priority patent/WO1988009164A1/fr
Priority to FR8713841A priority patent/FR2621485B1/fr
Publication of WO1988009164A1 publication Critical patent/WO1988009164A1/fr
Priority to GB8901641A priority patent/GB2213062B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin

Definitions

  • the scope of the invention is not subject to mediation, and this is mainly due to the fact that the drug is being treated in the United States.
  • Shi ⁇ ⁇ e is ⁇ lz ⁇ vayaie siya ⁇ e ⁇ iches ⁇ i ⁇ es ⁇ gen ⁇ v 'in ⁇ sledyaie g ⁇ dy ⁇ zv ⁇ lil ⁇ vyyavi ⁇ ⁇ yad se ⁇ ezyay ⁇ ⁇ b ⁇ ch- 15 yay ⁇ i ⁇ deys ⁇ vy.
  • the indicated drugs cause gay men and women and harmless people.
  • the inventive company possesses the expressed estrogen
  • the inventive device stimulates the development of brand and primary female rivals in the event of their underdevelopment. takes on common facilities arising from the lack of
  • Declare ⁇ réelle ⁇ ⁇ ... causes the process of synthesis and luteinizing hormones and the stimulating hormones to be activated in the process of gypsy and stimulates the process of evolving.
  • the inventive product is absorbed from the gastrointestinal tract and, when used internally, does not possess an irritating effect. In fact, it is not very toxic, it does not possess the reagent and cancerous properties. Declare that you may be
  • the claimed preparation was tested in humans and in humans.
  • the strenuous activity of the claimed drug was also experienced in mouse trials. At the same time, it was noted that the mass of the brand and increase the weight of the matrices by changing in it.
  • the active activity of the claimed product is in the case of obesity and spasms
  • the claimed preparation at a dose of 0.05 mg / kg caused leakage / estrus / in two well-developed mice of ulcer 10, at a dose of 0.1 mg / kg in 5 and at a dose of I mg / kg at all time.
  • the inventive preparation in doses of 0, I and I mg / kg for 5 days, stresses the manifestation of the effects.
  • the 2nd-5th act after the nursing of the males, at $ 80, there are vaginal dabs of the wounds.
  • the online group lasts 7-8 days. After the first experience of 19 years, the pregnancy was revealed, that the uncultured voles were found to be invisible, all the living things, I’ve forgotten.
  • the claimed preparation which is rooted in the family, causes injuries in food, accelerates the damage to the land and causes loss of health. ⁇ crusts that received I mg / kg of the claimed medication, in which the ⁇ - ⁇ 2 deformity occurs in the large area of a small immigrant, is immature.
  • the most pronounced method of treatment was protein metabolism in 20 skeletal muscles, and I studied cardiac arrhythmias.
  • the claimed preparation was administered in a dose of I mg / kg internally for 3 days.
  • the claimed preparation in the dose of I mg / kg is in good condition that it is free from any loss of health.
  • the results of the experiments are presented in tables 3 and 4.
  • estegeevy effect is claimed to be a preparation that is judging by the increase in mass, this is a common protein in it, so it is an active protein.
  • esthegy is a variable effect during the different seasons of the year.
  • the 30th group was able to increase to 20 mg, claimed by the manufacturer and the generator “on the contrary, increasing it already up to 85, 2 and 92, 5 mg, respectively.
  • the claimed preparation in the dose I mg / kg was administered at 15.00, the timed stage of diesestus-2 was oversized, and the accumulation was completed after 18 hours (200.9_6.9 ng / ml after 20 hours) 25 3.2 ng / ml), although I am different. thirdly, a third-party hotel in the gizmo.
  • the claimed drug was introduced into the estrus-2 estates, and more often than not it was possible to suppress the secretion of ulcerous ulcers.
  • ⁇ [- ⁇ ⁇ and introduction of it in a mouse is equal to 2220 mg / kg, for ⁇ 4700 mg / kg. 3 experiences on the occasion
  • the claimed preparation does not show the reaction and the terminal action, 5 but also does not affect the process.
  • the claimed preparation was pagan in 468 sick women. On-site groups at different clinics provided paired groups of white women who were treated with maternal / ethinyl-esthil / yale disease.
  • the invented drug was studied in the Republic of Poland and the English Empire in girls 12-16 years old. The most painful way to start the course is to carry out an examination, including: anesthetics, tests of functional diagnostics; I share the right to make sense, therefore, I was not happy with the external arrogance of six small lips; vaginal for identifying the condition of the neck; ultra-sound scanning of small businesses; Distribution of a wide area.
  • the inventive preepa-20 dose was prescribed in a dose of 5-10 mg per day, 20-day courses. Just 1-2 kursa.
  • the mammary glands are enlarged to the extent of the enlargement of the mammary glands.
  • the genital area was: “counted 25 times” of the mucous membranes of the vulva, except for the vaginal
  • the claimed preparation showed an active action - 16 - vyaye on an ugly gang are sick with different siblings ieriaus ⁇ ⁇ ’ 5 Gastrointestinal effects were not earlier than after 3-6 months of untreated treatment. In all patients, an abnormal menstrual reaction was observed. Comply with the sale of the product, there is a softer occupation and I’ll be absent
  • the starting 10 gosh,,,, ng / ml 11.0 * 2.6 19.1 * 4.9 8.5 * 2.6 11.0 * 2.7
  • the claimed medication was prescribed for 2.5-5 mg ⁇ I nect ⁇ per day for 12-14 days / I phase of the cycle /.
  • the claimed product does not suffer from a disastrous effect, has a mild, rapidly growing effect, which is beneficial for the ulcer
  • the declared preparations can be used in various medicinal forms / in tablets, candles, and other tablets /. I am the main dozers set yandyuadualno in the wilderness of the form of the disease. ⁇ réelle ⁇ réelle ⁇ Fort strig-
  • the claimed drug is indicated for diseases of the small glands and the disease of the mammary gland / get the glands / lapoma, endometrium /.
  • the method of allocating an active substance can be accomplished by the following method.
  • the claimed and treated product is used in a gynecological treatment for treating diseases associated with a defect in the function of an egg. ⁇ ⁇ tica ⁇

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Une préparation pharmaceutique ayant une action oestrogénique est composée d'un mélange de substances actives de -4-oxy-6-(41-oxybenzoyloxy)-dauc, 8,9-ane de la formule (I) avec 4-oxy-6-(41-oxybenzoyloxy)-8,9-époxydaucane de la formule (2) et d'un porteur pharmaceutique. La préparation pharmaceutique peut être réalisée sous la forme de cachets ayant une teneur en substances actives égale à 0,005 g par cachet.
PCT/SU1987/000065 1987-05-29 1987-05-29 Preparation pharmaceutique a action oestrogenique WO1988009164A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE19873790958 DE3790958T1 (de) 1987-05-29 1987-05-29 Arzneimittel mit oestrogener wirkung
CH3458987A CH672251A5 (fr) 1987-05-29 1987-05-29
JP87505402A JPH02500362A (ja) 1987-05-29 1987-05-29 エストロゲン効果を有する製剤
PCT/SU1987/000065 WO1988009164A1 (fr) 1987-05-29 1987-05-29 Preparation pharmaceutique a action oestrogenique
FR8713841A FR2621485B1 (fr) 1987-05-29 1987-10-07 Medicament a action oestrogene
GB8901641A GB2213062B (en) 1987-05-29 1989-01-26 Pharmaceutical preparation having oestrogen action.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SU1987/000065 WO1988009164A1 (fr) 1987-05-29 1987-05-29 Preparation pharmaceutique a action oestrogenique

Publications (1)

Publication Number Publication Date
WO1988009164A1 true WO1988009164A1 (fr) 1988-12-01

Family

ID=21617114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SU1987/000065 WO1988009164A1 (fr) 1987-05-29 1987-05-29 Preparation pharmaceutique a action oestrogenique

Country Status (6)

Country Link
JP (1) JPH02500362A (fr)
CH (1) CH672251A5 (fr)
DE (1) DE3790958T1 (fr)
FR (1) FR2621485B1 (fr)
GB (1) GB2213062B (fr)
WO (1) WO1988009164A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030661A1 (it) 2003-04-04 2004-10-05 Indena Spa Processo per la preparazione della ferutinina da piante del genere ferula

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1443023A (en) * 1972-10-19 1976-07-21 Hoechst Ag Process for preparing tablets and pills
GB1538280A (en) * 1975-04-21 1979-01-17 Armour Dial Inc Antacid tablets and processes for the preparation thereof
DE3116414A1 (de) * 1980-04-24 1982-04-01 Roussel-Uclaf, 75007 Paris "verwendung von substituierten derivaten der 4-phenyl-4-oxo-2-hydroxy-buttersaeure als arzneimittel"

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1443023A (en) * 1972-10-19 1976-07-21 Hoechst Ag Process for preparing tablets and pills
GB1538280A (en) * 1975-04-21 1979-01-17 Armour Dial Inc Antacid tablets and processes for the preparation thereof
DE3116414A1 (de) * 1980-04-24 1982-04-01 Roussel-Uclaf, 75007 Paris "verwendung von substituierten derivaten der 4-phenyl-4-oxo-2-hydroxy-buttersaeure als arzneimittel"

Also Published As

Publication number Publication date
DE3790958T1 (de) 1989-05-24
GB2213062A (en) 1989-08-09
GB8901641D0 (en) 1989-04-05
GB2213062B (en) 1990-03-14
FR2621485B1 (fr) 1990-02-16
CH672251A5 (fr) 1989-11-15
JPH02500362A (ja) 1990-02-08
FR2621485A1 (fr) 1989-04-14

Similar Documents

Publication Publication Date Title
Meissner et al. Use of gelatinized maca (Lepidium peruvianum) in early postmenopausal women
Dunglison A Dictionary of Medical Science...
WO2005102372A1 (fr) Compositions de correction de changements du systeme endocrinien humain dus a l'age et procede de fabrication d'une forme pharmaceutique sur la base de ces compositions
WO1995017902A1 (fr) Utilisation d'une souche du champignon fusarium comme producteur de substances et preparation a base celle-ci presentant, des proprietes, adaptogeniques et immunomodulatrices
WO1984002470A1 (fr) Preparation medicinale pour le traitement therapeutique d'ulceres peptiques
WO1990012584A1 (fr) Preparation ayant un action anti-inflammatoire, lactogene et stimulante, et procede pour sa fabrication
AU731286B2 (en) Composition and method for treating herpes simplex
Williams et al. INFLUENCE OF HORMONES UPON PHOSPHATASE CONTENT OF RAT FEMURS I. EFFECTS OFADRENAL CORTICAL SUBSTANCES AND PARATHYROID EXTRACT
WO2005068491A1 (fr) Peptides antitumoraux et antiviraux
Ayaz et al. Effect of green tea on blood pressure in healthy individuals: a meta-analysis
JP2019532039A (ja) 花粉及び／又は雌しべの抽出物を含む組成物、調製方法、並びに関連する使用
WO1994028153A2 (fr) Adn de faible masse moleculaire tiree de laitance d'esturgeon, procede d'obtention de l'adn et preparation pharmaceutique a base de celui-ci
WO1988009164A1 (fr) Preparation pharmaceutique a action oestrogenique
Torkashvand et al. Effectiveness of olea herbal ointment on episiotomy wound healing among primiparous women: A randomized clinical trial
EP3750532A1 (fr) Un complément alimentaire destiné à être utilisé pour restauration de l'attirance sexuelle chez l'homme (libido)
RU2259205C1 (ru) Лечебно-профилактическое средство при заболеванях мочеполовой системы у мужчин
Chaitow Candida Albicans: Could Yeast be Your Problem?
US20170333475A1 (en) Food Supplement for Restoring Male Sex Drive (Libido)
WO1998043613A1 (fr) Onguents pour traiter tous les stades de lesions suppuratives, brulures et ulcers trophiques, modes de preparation et applications
WO1995008318A2 (fr) Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse
Jillelamudi et al. Abortifacient activity of Aegle marmelos and Laurus nobilis leaf extracts
KR20080074583A (ko) 히알루론산으로 이루어지는 알러지 질환 예방 및 치료용약제, 식품 및 화장품
WO1991000098A1 (fr) Preparation anti-inflammatoire et son procede d'obtention
WO2006091804A2 (fr) Compositions et procedes pour le traitement de l'acne
CN112656887B (zh) 一种具有抗炎抗氧化的中药组合物、制剂及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CH DE GB HU JP US

RET De translation (de og part 6b)

Ref document number: 3790958

Country of ref document: DE

Date of ref document: 19890524

WWE Wipo information: entry into national phase

Ref document number: 3790958

Country of ref document: DE